Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies.
Immunotherapy
checkpoint inhibitors
cytotoxic T-lymphocyte antigen 4
programmed death ligand-1
programmed death receptor-1
Journal
Cancer drug resistance (Alhambra, Calif.)
ISSN: 2578-532X
Titre abrégé: Cancer Drug Resist
Pays: United States
ID NLM: 101738710
Informations de publication
Date de publication:
2019
2019
Historique:
received:
11
07
2019
revised:
05
09
2019
accepted:
27
09
2019
entrez:
18
5
2022
pubmed:
19
12
2019
medline:
19
12
2019
Statut:
epublish
Résumé
Recent advances in pharmacological immune modulation against tumor cells has dramatically changed the paradigm of cancer treatment. Checkpoint inhibitor therapy is a form of cancer immunotherapy already in clinical setting but also under active basic and clinical investigation. Nevertheless, some patients are primary unresponsive or develop ulterior resistance to these family of drugs. This review aims to update the basic molecular mechanism of resistance as well as the current strategies for checkpoint inhibitor selection in order to propose new approaches to individualize the use of these novel therapies.
Identifiants
pubmed: 35582274
doi: 10.20517/cdr.2019.61
pmc: PMC9019209
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
980-993Informations de copyright
© The Author(s) 2019.
Déclaration de conflit d'intérêts
All authors declared that there are no conflicts of interest.
Références
Cancer Res. 2016 Jan 15;76(2):227-38
pubmed: 26637667
Lancet Oncol. 2016 Oct;17(10):1374-1385
pubmed: 27592805
Nat Rev Cancer. 2013 Oct;13(10):739-52
pubmed: 24060865
Clin Cancer Res. 2013 Jan 15;19(2):393-403
pubmed: 23204132
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
J Natl Compr Canc Netw. 2019 May 1;17(5.5):574-578
pubmed: 31117034
Science. 2016 Jul 22;353(6297):399-403
pubmed: 27463676
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
N Engl J Med. 2003 Mar 6;348(10):919-32
pubmed: 12621137
Immunity. 1994 Dec;1(9):793-801
pubmed: 7534620
J Clin Oncol. 2013 Feb 10;31(5):616-22
pubmed: 23295794
J Clin Oncol. 2016 Sep 10;34(26):3119-25
pubmed: 27269937
Lancet Oncol. 2017 Sep;18(9):1261-1273
pubmed: 28729154
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Nat Rev Cancer. 2007 Feb;7(2):95-106
pubmed: 17251916
Int Immunol. 1996 May;8(5):765-72
pubmed: 8671665
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
Cell Res. 2017 Jan;27(1):109-118
pubmed: 27995907
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Lancet Oncol. 2018 Jan;19(1):51-64
pubmed: 29217288
Clin Lung Cancer. 2016 May;17(3):232-236.e1
pubmed: 27265743
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
J Clin Oncol. 2017 Jul 1;35(19):2193-2202
pubmed: 28471727
J Clin Oncol. 2008 Nov 10;26(32):5275-83
pubmed: 18838703
Cancer Res. 2009 Nov 15;69(22):8693-9
pubmed: 19861533
Blood. 2010 Oct 28;116(17):3268-77
pubmed: 20628145
Cancer Med. 2018 Mar;7(3):746-756
pubmed: 29436178
Lancet Oncol. 2013 Oct;14(11):1104-1111
pubmed: 24035405
Oncologist. 2019 Jun;24(6):e327-e337
pubmed: 30796151
Cancer. 2007 Dec 15;110(12):2614-27
pubmed: 18000991
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Cell. 2012 Sep 28;151(1):153-66
pubmed: 23021222
Cell. 2015 Apr 9;161(2):205-14
pubmed: 25860605
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Breast Cancer Res Treat. 2018 Feb;167(3):671-686
pubmed: 29063313
Blood. 2011 Aug 25;118(8):2254-65
pubmed: 21734236
Cell. 2008 May 30;133(5):775-87
pubmed: 18510923
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Science. 2016 Apr 8;352(6282):227-31
pubmed: 26966191
N Engl J Med. 2016 Dec 8;375(23):2255-2262
pubmed: 27959684
Lancet Oncol. 2016 Mar;17(3):299-308
pubmed: 26858122
J Exp Med. 2009 Jun 8;206(6):1327-37
pubmed: 19451266
J Thorac Dis. 2017 Oct;9(10):3480-3482
pubmed: 29268321
Gastroenterology. 2010 Jun;138(6):2073-2087.e3
pubmed: 20420947
Cancer Cell. 2004 Oct;6(4):409-21
pubmed: 15488763
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
Ann Oncol. 2014 Sep;25(9):1750-1755
pubmed: 24907635
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
JAMA Oncol. 2019 Feb 1;5(2):195-203
pubmed: 30383184
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
JAMA Oncol. 2017 Sep 14;3(9):e172411
pubmed: 28817753
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
Cancer Discov. 2016 Feb;6(2):202-16
pubmed: 26645196
Clin Transl Oncol. 2016 Mar;18(3):251-8
pubmed: 26264497
J Exp Med. 1991 Sep 1;174(3):561-9
pubmed: 1714933
J Clin Oncol. 2017 Jul 1;35(19):2117-2124
pubmed: 28375787
J Clin Oncol. 2019 Oct 1;37(28):2518-2527
pubmed: 31154919
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
J Hepatol. 2013 Jul;59(1):81-8
pubmed: 23466307
Cancer Discov. 2013 Dec;3(12):1355-63
pubmed: 24078774
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Cancer Immunol Immunother. 2014 Mar;63(3):247-57
pubmed: 24357148
Cell. 2016 Oct 6;167(2):397-404.e9
pubmed: 27667683
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
J Clin Oncol. 2009 Mar 1;27(7):1075-81
pubmed: 19139427
Front Oncol. 2019 Mar 26;9:191
pubmed: 30972299